EV-201 study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy Meeting Abstract


Authors: Rosenberg, J. E.; Heath, E. I.; O'Donnell, P. H.; Hahn, N. M.; Balar, A. V.; Gartner, E. M.; Melhem-Bertrandt, A.; Petrylak, D. P.
Abstract Title: EV-201 study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
Meeting Title: 2018 Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 6 Suppl.
Meeting Dates: 2018 Feb 8-10
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-02-20
Language: English
ACCESSION: WOS:000436179500535
DOI: 10.1200/JCO.2018.36.6_suppl.TPS542
PROVIDER: wos
Notes: Meeting Abstract: TPS542 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jonathan Eric Rosenberg
    510 Rosenberg